• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

侵袭性葡萄胎致单侧肾积水1例报告

Unilateral hydronephrosis caused by invasive mole: a case report.

作者信息

Zhang Hai-Yan, Wu Wei, Zhu Jin

机构信息

Department of Gynecology, The Obstetrics and Gynecology Hospital, Shanghai Medical College, Fudan University No.419 Fangxie Road, Shanghai, China.

出版信息

Int J Clin Exp Med. 2013 Oct 25;6(10):1010-4. eCollection 2013.

PMID:24260613
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3832344/
Abstract

Invasive mole belongs to gestational trophoblastic neoplasm, which is a highly curable group of pregnancy-related tumors. However, approximately 20% of gestational trophoblastic tumors will be resistant to or relapsed after initial chemotherapy. These resistant and relapsed lesions will require salvage chemotherapy with or without surgery. It is still unclear which regimens are the most effective and least toxic. Here, we report a case of unilateral hydronephrosis presenting 1 week after a history of curettage because of a hydatidiform mole. With the combination treatments of chemotherapy and surgery, the patient was cured.

摘要

侵蚀性葡萄胎属于妊娠滋养细胞肿瘤,这是一组治愈率很高的妊娠相关肿瘤。然而,大约20%的妊娠滋养细胞肿瘤在初始化疗后会出现耐药或复发。这些耐药和复发病变需要进行挽救性化疗,可能还需要手术。目前仍不清楚哪种治疗方案最有效且毒性最小。在此,我们报告一例因葡萄胎刮宫术后1周出现单侧肾积水的病例。通过化疗和手术的联合治疗,患者得以治愈。

相似文献

1
Unilateral hydronephrosis caused by invasive mole: a case report.侵袭性葡萄胎致单侧肾积水1例报告
Int J Clin Exp Med. 2013 Oct 25;6(10):1010-4. eCollection 2013.
2
Gestational trophoblastic diseases - clinical guidelines for diagnosis, treatment, follow-up, and counselling.妊娠滋养细胞疾病——诊断、治疗、随访及咨询临床指南
Dan Med J. 2015 Nov;62(11):A5082.
3
Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?对于既往有葡萄胎病史的患者,我们是否需要在产后进行人绒毛膜促性腺激素筛查以识别复发性妊娠滋养细胞疾病患者?
Eur J Obstet Gynecol Reprod Biol. 2019 Mar;234:117-119. doi: 10.1016/j.ejogrb.2018.12.029. Epub 2019 Jan 6.
4
Persistent gestational trophoblastic tumour with partial hydatidiform mole as the antecedent pregnancy.以部分性葡萄胎为前次妊娠的持续性妊娠滋养细胞肿瘤。
Br J Obstet Gynaecol. 1994 Apr;101(4):330-4. doi: 10.1111/j.1471-0528.1994.tb13620.x.
5
Gestational trophoblastic disease within an elective abortion population.选择性堕胎人群中的妊娠滋养细胞疾病
Am J Obstet Gynecol. 1979 Oct 15;135(4):452-4. doi: 10.1016/0002-9378(79)90429-0.
6
Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia.耐药或复发性妊娠滋养细胞肿瘤的化疗
Cochrane Database Syst Rev. 2012 Dec 12;12:CD008891. doi: 10.1002/14651858.CD008891.pub2.
7
An analysis of the influences of maternal age, gestational age, contraceptive method, and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy.对葡萄胎患者的母亲年龄、孕周、避孕方法及初次治疗方式对后续化疗发生率的影响进行分析。
Br J Obstet Gynaecol. 1979 Oct;86(10):782-92. doi: 10.1111/j.1471-0528.1979.tb10694.x.
8
Unusual Presentation of Invasive Mole: A Case Report.侵袭性葡萄胎的不典型表现:一例报告
J Reprod Infertil. 2017 Jan-Mar;18(1):205-209.
9
Reproductive outcomes after hydatiform mole and gestational trophoblastic neoplasia.葡萄胎和妊娠滋养细胞肿瘤后的生殖结局
Gynecol Endocrinol. 2015;31(9):673-8. doi: 10.3109/09513590.2015.1054803. Epub 2015 Aug 18.
10
Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease.二次刮宫治疗妊娠滋养细胞疾病的疗效——比利时妊娠滋养细胞疾病登记处的结果
Eur J Obstet Gynecol Reprod Biol. 2021 Feb;257:95-99. doi: 10.1016/j.ejogrb.2020.12.001. Epub 2020 Dec 8.

引用本文的文献

1
Unusual Presentation of Invasive Mole: A Case Report.侵袭性葡萄胎的不典型表现:一例报告
J Reprod Infertil. 2017 Jan-Mar;18(1):205-209.

本文引用的文献

1
Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.联合化疗用于高危妊娠滋养细胞肿瘤的初始治疗
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD005196. doi: 10.1002/14651858.CD005196.pub4.
2
Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.比较顺铂为基础的联合化疗与 EMA/CO 化疗治疗高危妊娠滋养细胞肿瘤。
Eur J Cancer. 2013 Mar;49(4):860-7. doi: 10.1016/j.ejca.2012.09.015. Epub 2012 Oct 23.
3
Gestational trophoblastic disease: a 21-year review of the clinical experience at an Argentinean public hospital.妊娠滋养细胞疾病:对一家阿根廷公立医院21年临床经验的回顾
J Reprod Med. 2012 Jul-Aug;57(7-8):341-9.
4
Role of adjuvant hysterectomy in management of high-risk gestational trophoblastic neoplasia.辅助性子宫切除术在高危妊娠滋养细胞肿瘤治疗中的作用。
Int J Gynecol Cancer. 2012 Mar;22(3):509-14. doi: 10.1097/IGC.0b013e31823f88e2.
5
Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia.经阴道超声预测 I 期低危滋养细胞肿瘤化疗反应延迟和耐药。
Ultrasound Obstet Gynecol. 2012 Jul;40(1):99-105. doi: 10.1002/uog.11097.
6
[Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high-risk hydatidiform mole].高危葡萄胎患者预防性化疗效果及临床特征分析
Zhonghua Fu Chan Ke Za Zhi. 2011 Jan;46(1):24-7.
7
Genetics of gestational trophoblastic neoplasia: an update for the clinician.妊娠滋养细胞肿瘤遗传学:临床医生的最新知识。
Future Oncol. 2010 Dec;6(12):1915-23. doi: 10.2217/fon.10.153.
8
Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.低危型妊娠滋养细胞肿瘤中 hCG 清除率对氨甲喋呤耐药风险的预测价值。
Ann Oncol. 2010 Aug;21(8):1643-1650. doi: 10.1093/annonc/mdq033. Epub 2010 Feb 12.
9
Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neoplasia.预测化疗耐药性妊娠滋养细胞肿瘤患者手术治疗反应的临床参数。
Gynecol Oncol. 2009 Jun;113(3):312-5. doi: 10.1016/j.ygyno.2009.02.025. Epub 2009 Apr 5.
10
Gestational trophoblastic neoplasia management: an update.妊娠滋养细胞肿瘤的管理:最新进展
Curr Opin Oncol. 2007 Sep;19(5):486-91. doi: 10.1097/CCO.0b013e3282dc94e5.